Lucintel's latest market report analyzed that in-vitro diagnostics provides attractive opportunities in the hospitals, laboratories, and home care end use industries. The in-vitro diagnostics market is expected to reach $127.3 billion by 2028 with a CAGR of 5%. In this market, infectious diseases is the largest segment by application, whereas laboratories is largest by end use industry.
Download Brochure of this report by clicking on https://www.lucintel.com/in-vitro-diagnostics-market.aspx
Based on application, the in-vitro diagnostics market is segmented into infectious diseases, diabetes, oncology, cardiology, nephrology, autoimmune diseases, drug testing, others. The infectious diseases segment accounted for the largest share of the market in 2023 and is expected to register the highest CAGR during the forecast period, due to growing number of life-threatening diseases, such as HIV/AIDS, tuberculosis, diphtheria, hepatitis, and pneumonia.
Browse in-depth TOC on “In-Vitro Diagnostics Market”
100 – Figures/Tables
150 – Pages
The In-Vitro Diagnostics Market is marked by the presence of several big and small players. Some of the prominent players offering in-vitro diagnostics include Abbott, bioMérieux, Bio-Rad, Siemens Healthineers, and Qiagen.
Request Sample Report:
https://www.lucintel.com/in-vitro-diagnostics-market.aspx
This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or click on this link helpdesk@lucintel.com.
About Lucintel
Lucintel, the premier global management consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, growth consulting, M&A, and due diligence services to executives and key decision-makers in a variety of industries. For further information, visit www.lucintel.com.